Quick Facts
| Property | Details |
|---|---|
| What it is | Creatine with an ethyl ester group bonded to the carboxylic acid, designed to improve lipid solubility |
| Primary Claims | Improved absorption over creatine monohydrate, reduced water retention, smaller effective dose |
| Standard Dosage | 3–6g/day; no loading phase (per manufacturer labeling) |
| Evidence Grade | C — Limited (one direct RCT, no meta-analyses; evidence does not support superiority over monohydrate) |
| Key Studies | Spillane et al. 2009 (PMID: 19228401); Hall & Trojian 2013 (PMID: 23851411); Andres et al. 2017 (PMID: 28019093) |
| Status | Marketed as advanced creatine form; clinical evidence does not support marketing claims |
Creatine ethyl ester entered the supplement market as a proposed upgrade to creatine monohydrate — the most extensively studied ergogenic supplement in sports nutrition. The esterification was intended to solve a problem that arguably did not exist: creatine monohydrate already demonstrates approximately 99% oral bioavailability. Below is an honest, evidence-based assessment of what CEE delivers and where the claims diverge from the data.
What Is Creatine Ethyl Ester?
Creatine ethyl ester is produced by bonding an ethyl ester group (–COOC₂H₅) to creatine’s carboxylic acid group through an esterification reaction involving creatine and ethanol under acidic catalysis. The resulting molecule has substantially higher lipophilicity than creatine monohydrate — the theoretical basis for marketing claims about improved cellular membrane permeability.
The rationale behind CEE development centers on one hypothesis: that esterification would allow creatine to passively diffuse across cell membranes without requiring the sodium-dependent creatine transporter (SLC6A8/CrT). Creatine monohydrate relies on this transporter for muscle uptake, and transporter saturation was proposed as a limiting factor. CEE was designed to bypass this bottleneck entirely.
However, the hypothesis encountered a fundamental pharmacokinetic obstacle. Andres et al. (2017) reviewed creatine forms intended for sports nutrition and documented that CEE is chemically unstable across physiological pH ranges, undergoing rapid cyclization to creatinine rather than hydrolysis to free creatine (PMID: 28019093). At strongly acidic pH (1.0), CEE has a half-life of approximately 570 hours — but as pH rises through the duodenum, jejunum, and blood (pH 5.0–7.4), the degradation rate increases linearly. The product reaching muscle tissue is substantially creatinine, not creatine.
How Does Creatine Ethyl Ester Work?
Creatine itself functions through the phosphocreatine energy shuttle. In muscle cells, creatine kinase phosphorylates creatine to phosphocreatine, which serves as a rapid-access energy reservoir. During high-intensity contractions lasting 5–15 seconds, phosphocreatine donates its phosphate group to regenerate ATP from ADP — maintaining power output when glycolytic and oxidative systems cannot meet immediate energy demands.
CEE was designed to deliver creatine to this system more efficiently than creatine monohydrate. The ethyl ester group increases the molecule’s partition coefficient, theoretically allowing passive diffusion across lipid bilayer membranes. If this mechanism worked as intended, CEE would bypass creatine transporter kinetics and deliver creatine directly to the intracellular compartment.
The problem is degradation timing. For CEE to deliver on its premise, the intact ester must survive gastric acid, intestinal transit, and bloodstream exposure long enough to reach muscle cell membranes — and then hydrolyze to free creatine inside the cell. The pH-dependent stability data from chemical analysis shows this sequence is unlikely to complete before cyclization to creatinine occurs. The ester does not survive long enough under physiological conditions to exploit its theoretical membrane advantage.
What Does the Clinical Evidence Show?
The most directly relevant study is Spillane et al. (2009), a randomized controlled trial published in the Journal of the International Society of Sports Nutrition (PMID: 19228401). Thirty resistance-trained men were randomized to CEE, creatine monohydrate, or placebo groups and completed 47 days of supplementation combined with heavy resistance training.
The results were unambiguous. Creatine monohydrate significantly increased serum creatine levels compared to both CEE and placebo. CEE did not produce significantly greater serum creatine elevations than placebo. Intramuscular creatine content — the metric that actually determines ergogenic potential — followed the same pattern: creatine monohydrate increased it; CEE did not produce superior loading compared to placebo.
On body composition, strength, and power outcomes, all groups improved across the training period — but these improvements tracked with the resistance training program itself, not with supplementation group assignment. CEE offered no measurable ergogenic advantage over placebo, while creatine monohydrate demonstrated the expected performance benefits consistent with its extensive evidence base.
Hall and Trojian (2013) reviewed the broader creatine supplementation literature for Current Sports Medicine Reports and stated directly that “other forms such as creatine ethyl ester have not shown added benefits” over creatine monohydrate (PMID: 23851411). This conclusion aligns with the mechanistic degradation data: a compound that converts primarily to creatinine before reaching muscle cannot match a compound that delivers intact creatine.
How Does CEE Compare to Creatine Monohydrate?
| Parameter | Creatine Monohydrate | Creatine Ethyl Ester |
|---|---|---|
| Oral bioavailability | ~99% (well-established) | Unknown; likely lower due to creatinine conversion |
| Muscle creatine loading | Significant increase (multiple RCTs) | No significant increase vs. placebo (Spillane 2009) |
| Serum creatinine elevation | Modest, dose-dependent | Greater than monohydrate (degradation product) |
| Loading phase | 20g/day × 5–7 days (optional) | Not recommended (manufacturer); no clinical protocol |
| Evidence base | >500 peer-reviewed studies | <10 directly relevant studies |
| Cost per effective gram | Low ($0.03–0.06/g) | Higher ($0.10–0.20/g) |
| ISSN position | Gold standard recommendation | Not recommended over monohydrate |
The comparison is not close. Creatine monohydrate has the most extensive evidence base of any sports nutrition supplement. CEE was positioned as an improvement but the clinical data does not support that positioning.
Who Uses Creatine Ethyl Ester?
CEE continues to have a market presence primarily among consumers who report gastrointestinal discomfort with creatine monohydrate (bloating, cramping, or water retention). The anecdotal reports of improved GI tolerance with CEE have not been validated in controlled trials, but they represent the most common reason consumers cite for choosing this form.
Athletes, bodybuilders, and recreational fitness users who have tried creatine monohydrate and experienced side effects sometimes switch to CEE or creatine hydrochloride (HCl) as alternatives. From an evidence standpoint, creatine HCl has a stronger theoretical basis for improved solubility, though it also lacks the clinical evidence depth of monohydrate.
References
- Spillane M, Schoch R, Cooke M, et al. The effects of creatine ethyl ester supplementation combined with heavy resistance training on body composition, muscle performance, and serum and muscle creatine levels. J Int Soc Sports Nutr. 2009;6:6. PMID: 19228401
- Hall M, Trojian TH. Creatine supplementation. Curr Sports Med Rep. 2013;12(4):240-244. PMID: 23851411
- Andres S, Ziegenhagen R, Trefflich I, et al. Creatine and creatine forms intended for sports nutrition. Mol Nutr Food Res. 2017;61(6). PMID: 28019093
- van der Meijden WA, et al. Impaired renal function: be aware of exogenous factors. Ned Tijdschr Geneeskd. 2013;157(25):A6092. PMID: 23759178